 |
 |
 |
 |
|
|
|
|
 |
|
|
 |
|
|
|
|
| |
|||||||||||||||||
|
|
|
|
|
|
|
|||||||||||
|
|||||||||||||||||
|
|
EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript
|
|
|
Dispatch Tuberculosis due to Resistant Haarlem Strain, TunisiaHelmi Mardassi,* Suggested citation for this article
The ability of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis to cause epidemics and spread globally contrasts with the initial perception that MDR tuberculosis (MDR-TB) has a reduced potential for transmission (1,2). In this respect, the W/Beijing type appears to be most common in humans and accounts for most reported MDR-TB outbreaks (3). In this report, we provide evidence for the epidemic potential of another worldwide prevalent M. tuberculosis genotype, namely, the Haarlem family (4,5). The identified strain is MDR and has rapidly expanded within immunocompetent and nonhospitalized patients. The StudyM. tuberculosis isolates were obtained from the Laboratory of Mycobacteriology of the Institut Pasteur de Tunis as part of the National Tuberculosis Surveillance Program. All samples (884 specimens) from patients with suspected TB residing in northern Tunisia (Bizerte) from August 2001 to October 2003 were forwarded to us by the referral regional hospital. This hospital serves a region with 483,086 people and an area of 3,501 km2. The incidence of TB in this area from 2001 to 2002 was 29/100,000 male patients and 11/100,000 female patients. All patients received the standard chemotherapy regimen of the Tunisian National Tuberculosis Program, i.e., 2 months of rifampicin, isoniazid, pyrazinamide, and streptomycin, followed by 4 months of rifampicin and isoniazid (2RHZS/4RH). This regimen was introduced into the region in 1995. Of the 193 M. tuberculosis isolates recovered, 20 were MDR. The corresponding patients were interviewed, and detailed epidemiologic investigations were conducted according to described protocols (6). In April 2004, while the study was in progress, a new MDR case was diagnosed. Analyses by IS6110 restriction fragment length polymorphism (IS6110 RFLP), ligation-mediated polymerase chain reaction (PCR), and spoligotyping were carried out by using standard protocols (7–9). Typing of the polymorphic GC-rich repetitive sequence (PGRS) with probe MTB484 (1) was conducted according to a previously reported protocol (10), with the exception that DNA was digested with AluI. Isolates were assigned to principal genetic groups according to the polymorphisms in the katG and gyrA genes (11). The following primer pairs were used to sequence rpoB, katG, and pncA gene mutations that confer resistance to rifampicin, isoniazid, and pyrazinamide, respectively: rpoB (5´-ATCACACCGCAGACGTTG-3´, 5´-TGCATCACAGTGATGTAGTCG-3´); katG (5´- CGTCGAAACAGCGGCGCTGA-3´, 5´-CAAGCGCCAGCAGGGCTCTT-3´); and pncA (5´-GGCGCACACAATGATCGGTG-3´, 5´-GCTTTGCGGCGAGCGCTCCA-3´). The recently described single nucleotide polymorphisms in putative M. tuberculosis mutator genes mutT1, mutT2, mutT3, and ogt were investigated with the same protocol reported by Rad et al. (12). DNA sequencing was conducted directly on the purified PCR products by using the Prism Ready Reaction Dye Deoxy Terminator Cycle sequencing kit on an ABI Prism 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA). Epidemiologic and clinical data indicated that all patients with MDR-TB were male with a mean age of 31 years at diagnosis (Table 1). All were Tunisians and permanently resided in the northern part of the country (Bizerte). All patients were seronegative for HIV with no documented history of travel abroad, and none had a history of immunosuppression, diabetes, or respiratory diseases other than TB. Mapping of the 21 patients with MDR-TB according to their residence sites showed that they were mostly scattered over the northeastern part of the region (surface area ≈1,000 km2) with no concentration in a particular locality (data not shown). Resistance to 5 first-line drugs was observed for most isolates (Table 2).
As indicated in Table 1, with the exception of patient P20, the DNA samples subjected to molecular typing were obtained from the initial isolate of all new patients. RFLP showed that 18 patients had nearly identical IS6110 profiles (Figures 1 and 2). The predominant profile (occurring in 13 patients) showed 11 bands, while the remaining 5 patients had an additional IS6110 band. The presence or absence of the additional IS6110 band was not restricted to new or previously treated patients. The RFLP pattern of patient P11, a new patient, clearly showed a mixture of the 12-band profile and some additional IS6110 bands (Figure 2A). Typing of his follow-up culture, which was obtained after 6 months of directly observed short-course therapy, as recommended by the World Health Organization, yielded only the 12-band profile (Figure 2A). Laboratory records and epidemiologic data indicate that this patient likely had a dual infection. The isolate from patient P13 was typed by ligation-mediated PCR. Its profile was identical to the 18 other MDR isolates. Thus 19 patients with MDR-TB could be clustered according to IS6110-based typing. Effective epidemiologic links were identified for 9 (47%) patients (Table 1). Another similar RFLP pattern was observed for patient P20. It shows 10 IS6110 bands (Figure 2B), 9 of which are common to the 12-band RFLP pattern described for the other isolates. The isolate from patient P19 displayed a 9-band IS6110 profile that was clearly distinct from all the other patients with MDR-TB (data not shown). With the exception of patient P19, the MDR isolates were identical in their PGRS profile (Figure 2) and spoligotype patterns (Table 2), which is characteristic of the Haarlem3 type (4). Sequence analysis of mutator and drug resistance genes conclusively confirmed that the 19 MDR isolates with nearly identical IS6110 (both 12- and 11-band profiles) are genetically closely related. They all harbor the L209L, T15S, S531L, and S315T mutations in mutT3, ogt, rpoB, and katG genes, respectively (Table 2), whereas mutT1 and MutT2 showed a wild type genotype (data not shown). The occurrence of an additional uncommon mutation in the rpoB gene (V610M) confirmed the clonality of this MDR Haarlem strain since it was present only in 19 patients with MDR-TB. The variability of resistance to pyrazinamide and the mutational profile within the pncA gene (Table 2) strongly suggest that primary transmission from person to person occurred mainly with a strain that was simultaneously resistant to isoniazid and rifampicin. To extend our analysis of the situation that prevailed in this region, samples from 143 (83%) of 172 patients without MDR strains were spoligotyped. Of these 143 patients, 41 (29%) were female. Overall, 31 (22%) of the 143 patients had Haarlem3 genotype TB. In contrast to the MDR-TB outbreak that involved only men, 6 women had a non-MDR Haarlem3 strain. Aside from the absence of clustering, ligation-mediated PCR typing showed that none of these non-MDR Haarlem3 isolates displayed a profile similar to the 19 MDR isolates involved in the transmission chain. Sequencing of the rpoB gene of 10 isolates randomly selected from the 31 non-MDR Haarlem isolates showed the absence of the outbreak-associated mutation V610M. This finding is strongly indicative of a true clonal expansion and a typical MDR-TB outbreak. The W/Beijing type was absent in the analyzed pool of isolates. ConclusionsThe results indicate that an MDR strain of M. tuberculosis has been actively transmitted among 19 HIV-negative male patients in Tunisia. Several observations indicate that this particular Haarlem strain displays increased transmissibility, virulence, or both. First, the outbreak peaked suddenly within a relatively short period of 21 months; 17 new cases (89%) were reported from September 2001 to June 2003. Inspection of the hospital register for 2000 showed only 3 new patients with MDR isolates, including outbreak-associated patients P5 and P7 (Table 1). Second, no epidemiologic links or contact points could be traced for several patients, which suggests that brief exposure would have been sufficient for effective transmission. Because patients with MDR-TB do not respond to treatment, they may serve as constant sources of transmission. Such a situation is likely to have occurred for the patients with established epidemiologic links. Third, the incidence of TB in the region in which the outbreak occurred is not particularly high. Fourth, patients were seronegative for HIV with no history of treatment causing immunosuppression. Fifth, no AIDS-associated TB outbreak that might have increased the adaptability of the strain within the indigenous population had occurred in the region. Sixth, although the Haarlem strain was MDR, it was able to cause an outbreak in those vaccinated with bacille Calmette-Guérin and in persons who were not hospitalized. Among the identified M. tuberculosis strain families (4,5), the W/Beijing type has been associated with outbreaks or microepidemics worldwide (3). The Haarlem strain family appears to be widespread (4), but its ability to cause outbreaks has been reported only twice, once in Argentina (13) and once in the Czech Republic (14). The distinctive feature of the present Haarlem MDR-TB outbreak is its accelerated transmission compared with the first 2 MDR-TB outbreaks. Alterations within DNA repair genes (mutator genes) are thought to favor the emergence of MDR strains with an increased adaptability (12). In this respect, both W/Beijing and Haarlem strains accumulated mutations within their putative mutator genes. Widespread MDR strains might also benefit from their intrinsic adaptability (15). From an epidemiologic point of view, TB programs must conduct extensive surveillance of MDR strains of M. tuberculosis strain families because they might cause serious outbreaks. Acknowledgments
References
Suggested citation
for this article: |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||
|
||||||||||||
|
|
|
|
|
EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z |
|
|
|
|
This page
posted May 12, 2005 |
|
|
|
|
Emerging
Infectious Diseases Journal |
|
|
